After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...
The CHLA-developed app will collect data for future research in machine learning to detect sleep disorders and help advance the standards of pediatric care in pain and sleep medicine Children’s ...
Children’s Hospital Los Angeles has launched the nation’s first pediatric sleep registry using Apple Watch technology, along with a new data collection app aimed at transforming how sleep disorders ...
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
Allschwil, Switzerland – March 30, 2026 Idorsia Ltd (SIX: IDIA) announces positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant – the company ...
LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
A new study conducted by University Hospitals Connor Whole Health highlights the impact of pediatric integrative medicine services. This unique self-governed program, operating within UH Rainbow ...
Pediatric concussions are a growing concern, particularly among youth engaged in sports and other high-risk activities. While much research has focused on cognitive rest and physical recovery, recent ...
Pediatric sleep studies, entailing knowledge, screening, evaluation and treatment practices regarding sleep disorders in children, are often unspoken of. According to Child Uplift, Inc., less than two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results